Archive for the ‘Gene Therapy Research’ Category

Genes2
The latest in genetic engineering

By: 99DarkHorses

More here:
Genes2 - Video

Washington, January 27 (ANI): Researchers at Washington University in St. Louis have found new genetic differences in hearts with disease.

The finding might explain gender differences in heart disease and ultimately lead to personalized treatment of various heart ailments.

Generally, men are more susceptible to developing atrial fibrillation, an irregular, rapid heartbeat that may lead to stroke, while women are more likely to develop long-QT syndrome, a rhythm disorder that can cause rapid heartbeats and sudden cardiac death.

While prior studies have clearly established differences in the development of heart disease between men and women, very few studies had looked at the molecular mechanisms behind those differences in human hearts.

Igor Efimov, PhD, the Lucy and Stanley Lopata Distinguished Professor of Biomedical Engineering in the School of Engineering and Applied Science at Washington University in St. Louis, and a former doctoral student, Christina Ambrosi, PhD, analyzed 34 human hearts looking for genetic differences.

The team took advantage of the unique opportunity at the university to obtain failing human hearts at the time of transplantation from Barnes-Jewish Hospital and non-failing hearts unsuitable for transplantation from Mid-America Transplant Services, a St. Louis-based organ procurement service.

The team screened for 89 major genes in electrophysiology, ion channel subunits, calcium handling proteins and transcription factors important in cardiac conduction and in the development of arrhythmia and the left atria and ventricles in human hearts.

"What was striking in this study is that we expected very large gender differences in expression of genes in the ventricles, but we did not find such differences. Unexpectedly, we found huge gender differences in the atria," said Efimov, also a professor of medicine, of radiology and of cell biology and physiology at Washington University School of Medicine.

The results showed that women with failing hearts have a weaker system of gene expression than men - males showed overall higher expression levels of nearly all of the 89 genes than women.

Women showed particularly lower atrial expression levels of several important genes encoding for potassium channels, including Kv4.3, KChIP2, Kv1.5 and Kir3.1. In fact, the atria of women with heart disease had less than half of the KChIP2 mRNA than atria in men.

Read the original:
Genes provide clues to differences in heart disease between men and women

LONDON--(BUSINESS WIRE)--

Inventages (a global healthcare venture capital fund backed by Nestl) announced today that they are working with SAP AG to integrate a comprehensive and mechanism-based approach to disease management with best-in-class IT frameworks to develop the next generation of personalized medicine companies.

Personalized medicine uses genetic and non-genetic information, such as environmental factors, to individualize the prevention, diagnosis, and treatment of disease. However to date, these solutions have typically been fragmented and incomplete, only addressing a subset of influencing factors. The personalized medicine solutions of the future will be holistic; integrating a patients genomic information, medical history, environmental and lifestyle factors. This holistic approach to managing disease will require the integration of multiple data sources and the structuring and analysis of large data volumes. This capability will be a key differentiator in ensuring the success and longevity of a personalized medicine solution.

This collaboration between a global healthcare venture capital fund and one of the worlds leading IT companies aims to provide emerging healthcare companies with both capital and extensive expertise and resources. The collaboration plans to leverage Inventages experience in developing highly efficacious clinically validated products and SAPs expertise in building and operating complex IT platforms and ecosystems.

Inventages has been looking at personalized medicine for several years and consequently we recognize that the future of disease management needs to be holistic; all of the factors that influence a patients health need to be considered. Inventages and SAP are aligned in their vision to advance personalized medicine through the use of information technology. This collaboration plans to provide our companies with access to SAPs unique capabilities and resources in mobile, cloud and big data processing, said Dr Gunnar Weikert, Chairman and Managing Partner of Inventages.

We are excited about this opportunity to collaborate with Inventages and Nestl, and combine our complementary capabilities in healthcare and IT, said Dr. Stefan Sigg, senior vice president, SAP HANA, SAP AG. Inventages and Nestl bring deep unbiased expertise in healthcare technology development including the design and running of clinical trials, as well as navigation of the complex regulatory and reimbursement environments. We are confident that this collaboration will help to identify and develop innovative healthcare solutions with the goal of improving peoples lives.

About Inventages

# # #

SAP and all SAP logos are trademarks or registered trademarks of SAP AG in Germany and in several other countries.

All other product and service names mentioned are the trademarks of their respective companies.

Visit link:
Inventages Announce They Are Working with SAP to Develop the Next Generation of Personalized Medicine Companies

Washington, Jan 28 (IANS) Even though healthy men and women have similarly structured hearts, the US researchers have discovered genetic differences in diseased hearts.

The new genetic differences found by researchers from Washington University in St. Louis in diseased hearts could pave the way to personalised treatment of various heart ailments.

Generally, men are more susceptible to developing atrial fibrillation, an irregular, rapid heartbeat that may lead to stroke, while women are more likely to develop long-QT syndrome, a rhythm disorder that can cause rapid heartbeats and sudden cardiac death, the journal Public Library of Science ONE reports.

Igor Efimov, professor of biomedical engineering at the Washington University School of Engineering & Applied Science, and former doctoral student Christina Ambrosi analysed 34 human hearts, looking for genetic differences that might explain gender differences in heart disease, according to a Washington statement.

The team screened for 89 major genes in electrophysiology, ion channel subunits, calcium handling proteins and transcription factors important in cardiac conduction and in the development of arrhythmia (irregular heartbeats) and the left atria (upper chambers) and ventricles (lower chambers) in human hearts.

"What was striking in this study is that we expected very large gender differences in expression of genes in the ventricles, but we did not find such differences," says Efimov, also professor of medicine, radiology and cell biology and physiology at Washington School of Medicine.

"Unexpectedly, we found huge gender differences in the atria," the professir said.

The results showed that women with failing hearts have a weaker system of gene expression than men -- males showed overall higher expression levels of nearly all of the 89 genes than women.

"When women have the highest levels of estrogen, they are least vulnerable to arrhythmia -- women are protected by estrogen," Efimov says. "But after menopause, women develop atrial fibrillation at the same rate as men. We don't understand this and need to study this in humans."

Continued here:
Genetic disparity marks male, female hearts

Chapters 5 and 6 Genetics Part 1r audio

By: Jeanne Calvert

Continued here:
Chapters 5 and 6 Genetics Part 1r audio - Video

Dihybrid Cross Review
This video reviews the basics with Dihybrid Crosses in Genetics and offers students two different ways to solve these types of problems.

By: Charles Filipek

View post:
Dihybrid Cross Review - Video

Incomplete Dominance Review
This video reviews the basics of Incomplete Dominance in Genetics and includes sample problems.

By: Charles Filipek

Read the original here:
Incomplete Dominance Review - Video

Co-Dominance Review
The video reviews Co-Dominance in Genetics and includes sample problems.

By: Charles Filipek

More here:
Co-Dominance Review - Video

Getting Rid Cellulite Up Front Reviews of Getting Rid of Cellulite
http://www.com-release.com Click on The Link If you #39;re ready for getting rid of cellulite Precisely what is more, make sure you dramatically reduced your intake of rather-simple carb supply sugar combined with choose complex carbohydrate supply including nutritional fibre. The vitality founded upon complex carbohydrate food becomes discharged more slowly in your body, continues to keep you full for prolonged allowing it to plus improve bowel motion. Consider that constipation leads to immensely to the event involving cellulite. So that you should eat a great deal of vegetables and fruit, grain and furthermore dried beans. A diet plan is really a time period thankful method to get rid of cellulite and the entire body unwanted fat. Numerous people express doing exercises plus diets is more than rated , nor accomplish the task. I #39;m sure that the majority of individuals which proclaim the following make " up " standard excuses with a loss in perseverance and also your self willpower. Getting yourself into descent shape continually demands tasks, and also to remain very happy to try to get hold of what you look for. A number of us that are taking part in incorrect factors to reduce pounds. You will discover differing plenty solutions obtainable, along with some are definitely more well suited for pre-determined most people than the others. Discover a good diet plan or alternatively fitness program which fits your life-style which will then aid you in getting rid of cellulite and also ...

By: gettingridcellulite

Original post:
Getting Rid Cellulite Up Front Reviews of Getting Rid of Cellulite - Video

Genetics 1
Wolverine Tutors discusses the basis of genetics, such as genes, alleles, chromosomes, and other topics. *I do not own any of the images or video in this video.

By: Manoj Kowshik

View post:
Genetics 1 - Video

Cancer Awareness
Cancer Awareness. http://www.CancerUncensored.com. Welcome to today #39;s issue of cancer uncensored. Hi, I #39;m Chris, and I am the author of cancer uncensored, a step-by-step guide to cancer prevention, early detection and cancer survival. In today #39;s video,I want to present you with an overview of cancer. I #39;m going to briefly talk about what cancer is, what triggers it, what the symptoms are, how you can actively avoid it. We will also go over current treatment methods and alternative medicine. I will also show you where you should go to get the most up-to-date news and breakthroughs. Before we get stuck in, I would like to address two points Firstly, most people are afraid of cancer. I can fully understand that, as my wife has cancer, but as a society, we must not let the fear of the disease prevent us from taking steps to understand it, as that way we can actively prevent it. One in three of us will be diagnosed with cancer within our lifetimes, and yet 85% of cancer is preventable! This video, and my book, cancer uncensored, will tell you how. So take in as much of this data as you can, because it could save your life. Secondly, you need to realise that cancer isn #39;t fully understood. We have a number of very solid theories, and plenty of study data, but if cancer was fully understood, we might be closer to a cure. To quote Thomas Edison, "The doctor of the future will no longer treat the human frame with drugs, but rather will cure and prevent disease with nutrition." But as ...

By: CancerUncensored

Follow this link:
Cancer Awareness - Video

Cancer Help - Help With Cancer
Cancer Help. http://www.CancerUncensored.com. Welcome to today #39;s issue of cancer uncensored. Hi, I #39;m Chris, and I am the author of cancer uncensored, a step-by-step guide to cancer prevention, early detection and cancer survival. In today #39;s video,I want to give you an overview of cancer. I am going to briefly talk about exactly what cancer is, what triggers it, what the symptoms are, how you can actively prevent it. We will also cover current treatment procedures and alternative treatment. I will also let you know where you can go to obtain the most up-to-date news and breakthroughs. Before we get stuck in, I ought to address two points Firstly, people are afraid of cancer. I can understand that, as my wife has recently been diagnosed with cancer, but as a society, we mustn #39;t allow the fear of the disease prevent us from taking steps to understand it, because that way we can actively prevent it. One in three of us will be diagnosed with cancer during our lifetimes, and yet 85% of cancer is avoidable! This video, and my book, cancer uncensored, can tell you how. So take in as much of this data as you can, because it could save your life. Secondly, you need to realise that cancer is not entirely understood. We have quite a few very solid theories, and plenty of study data, but if cancer was fully understood, we might be even closer to a cure. To quote Thomas Edison, "The doctor of the future will no longer treat the human frame with drugs, but rather will cure and prevent disease ...

By: CancerUncensored

Original post:
Cancer Help - Help With Cancer - Video

Seattle Genetics Inc. ( SGEN ) and Takeda Pharmaceutical Company Limited ( TKPYY ) recently announced the commencement of a global phase III study (ECHELON-2) on their oncology treatment, Adcetris (brentuximab vedotin). Adcetris (brentuximab vedotin) plus chemotherapy will be evaluated for the front-line treatment of CD30-positive mature T-cell lymphoma (MTCL) including in patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas.

We note that study is being conducted under the U.S. Food and Drug Administration's (FDA) Special Protocol Assessment (SPA) program. Seattle Genetics said that the European Medicines Agency (EMA) also provided scientific advice for the study. The randomized, double-blind, controlled study will enroll roughly 300 patients and will be conducted in North America, Europe and Asia.

Seattle Genetics and Takeda had presented encouraging phase I data on Adcetris at the American Society of Hematology (ASH) annual meeting in Dec 2012. Adcetris is currently approved in the US for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not suitable for ASCT and the treatment of sALCL in treatment-experienced patients. Adcetris is approved in the EU as well.

Our Take

We are positive on Seattle Genetics' efforts to expand Adcetris' label. Approval in the front-line setting will boost Adcetris' sales signifcantly. Adcetris net revenue in the third quarter of 2012 was $33.7 million and for the nine months ending Sep 30, 2012 was $102.8 million.

Seattle Genetics carries a Zacks Rank #3 (Hold). Right now Agenus Inc. ( AGEN ), Valeant Pharmaceuticals International, Inc. ( VRX ) and Targacept, Inc. ( TRGT ) look more attractive with a Zacks Rank #1 (Strong Buy).

AGENUS INC (AGEN): Free Stock Analysis Report

SEATTLE GENETIC (SGEN): Free Stock Analysis Report

(TKPYY): ETF Research Reports

TARGACEPT INC (TRGT): Free Stock Analysis Report

Here is the original post:
SGEN/Takeda's Adcetris Progresses - Analyst Blog

BOTHELL, Wash. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas. The trial, also known as ECHELON-2, is being conducted under a Special Protocol Assessment (SPA) agreement from the U.S. Food and Drug Administration (FDA) and also received scientific advice from the European Medicines Agency (EMA). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30. ADCETRIS is currently not approved for use in the front-line treatment of MTCL.

The standard of care for newly diagnosed MTCL, a chemotherapy regimen called CHOP, has not changed in more than three decades, and there is a significant need to identify enhanced treatment options for these patients, said Clay B. Siegall, Ph.D., President and Chief Executive Officer at Seattle Genetics. Recent phase I data from 26 patients presented at the ASH annual meeting showed that adding ADCETRIS to CHP resulted in compelling antitumor activity, with 100 percent of the patients experiencing a response, and a manageable safety profile. Our goal with this phase III trial is to redefine the standard of care for front-line treatment of MTCL.

This is the third global phase III trial with ADCETRIS to be initiated in the past nine months, said Karen Ferrante, M.D., Chief Medical Officer, Millennium. This trial represents another major achievement in our aspiration to bring important new therapies to patients with CD30-expressing malignancies by evaluating ADCETRIS in the front-line setting.

The ECHELON-2 study is a randomized, double-blind, placebo-controlled multi-center global phase III trial designed to investigate ADCETRIS in combination with cyclophosphamide, doxorubicin and prednisone (A+CHP) versus cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) as front-line therapy in patients with CD30-expressing MTCL. The primary endpoint is progression-free survival (PFS) per independent review facility assessment using the Revised Response Criteria for malignant lymphoma (Cheson, 2007). Secondary endpoints include overall survival (OS), complete remission (CR) rate and safety. The trial will be conducted in North America, Europe and Asia and is expected to enroll approximately 300 patients (approximately 150 patients per treatment arm). A molecular companion diagnostic test will be used in this trial to identify eligible patients based on CD30 expression. The companion diagnostic test is being developed under a previously announced collaboration agreement with Ventana Medical Systems, Inc. (Ventana), Millennium and Seattle Genetics.

At the recent 54th American Society of Hematology (ASH) Annual Meeting and Exposition held December 8-11, 2012 in Atlanta, GA, encouraging phase I data were presented from an abstract titled Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy as Front-line Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas (Abstract #60). The clinical trial was conducted to evaluate ADCETRIS in combination with chemotherapy for the treatment of newly diagnosed MTCL patients, including patients with sALCL. Data were reported from 26 previously untreated patients who received the combination regimen of ADCETRIS plus CHP.

After completing a combination regimen of ADCETRIS plus CHP, 26 of 26 patients (100 percent) treated with ADCETRIS plus CHP had an objective response, including 23 patients (88 percent) with a complete remission. The most common treatment-emergent adverse events of any grade regardless of relationship occurring in more than 30 percent of patients were nausea (62 percent), peripheral sensory neuropathy (62 percent), diarrhea (58 percent), fatigue (54 percent) and alopecia (46 percent). The most common Grade 3 or 4 treatment-emergent adverse events regardless of relationship included Grade 3 febrile neutropenia, peripheral sensory neuropathy, nausea and dyspnea and Grade 4 nausea and diarrhea. The abstract can be found at http://www.hematology.org.

More information about the ECHELON-2 phase III trial of ADCETRIS in front-line CD30-expressing MTCL, including enrolling centers, will be available by visiting http://www.clinicaltrials.gov.

About ADCETRIS

ADCETRIS (brentuximab vedotin) is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

Go here to see the original:
Seattle Genetics and Millennium Initiate Global Phase III Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Front ...

* Save my soul * - Stargate Atlantis -
I have only one word, as John Sheppard! hahahaha .. Between side effects of gene therapy on the wraith, and fratricidal wars of the nation wraith.

By: ManofMysteria

Follow this link:
* Save my soul * - Stargate Atlantis - - Video

Exercising immediately after receiving a flu vaccine enhances the effectiveness of the vaccine, according to researchers at Iowa State University. In the study, young adults who received the flu vaccine either participated in a mild-to-moderate exercise regimen for 90 minutes immediately after receiving the vaccine, or remained sedentary for 90 minutes. Participants who exercised immediately after receiving the vaccine showed a greater level of antibody production than students who remained sedentary. Presumably the higher level of antibody production would better protect the participants who exercised against the flu, but apparently that wasn’t specifically tested in this study. (The study has not yet been published in a peer-reviewed journal.)

The mechanism whereby exercise enhances the effectiveness of the flu vaccine isn’t known yet. The study’s lead researcher speculates that by improving blood flow to some tissues, exercise may speed the delivery of the vaccine to the lymph nodes, where most antibody production takes place. But that remains to be tested.

So go ahead and exercise immediately after the flu shot if you want to: it appears to do more good than harm.Source:
http://humanbiologyblog.blogspot.com/2013/01/exercise-and-flu-vaccine.html

Cardiac cell therapy- a realistic concept for elderly patients

By: Amr Arafat

View post:
Cardiac cell therapy- a realistic concept for elderly patients - Video

Southern California Dermatologist Dr. Tess Mauricio Talks Knees and Regenerative Cell Therapy
America #39;s Favorite Dermatologist, Dr. Tess Mauricio, is in her Del Mar clinic talking to Ruben Galvan about Regenerative Cell Therapy and the miracles it can do to those with bad or aching knees. She is joined by her patients Patrick, founder of Health Beauty Life media company, and Rico, a personal trainer. Dr. Tess is a world-renowned cosmetic dermatologist, physician trainer, researcher, and media personality. You #39;ve seen her in everything from Cosmo Magazine UK and San Diego Living to national shows like The Rachael Ray Show, America #39;s Next Top Model, and The Doctors. A graduate of Stanford University School of Medicine, she was the youngest woman president of the San Diego Society for Dermatologic Surgery, trained hundreds of other physicians from London to Asia, crowned Mrs. Philippines San Diego in 2011, and is a "FWN 100 Most Influential Women" awardee. Dr. Tess also hosts her own talk show, RSVP. Scripps Ranch Dermatology Cosmetic Center, San Diego CA M Beauty by Dr. Tess now open in National City, Glendale, and Del Mar/Solana Beach! http://www.mbeautyclinic.com http://www.tessmd.com rsvptalkshow.com

By: awPVT

Excerpt from:
Southern California Dermatologist Dr. Tess Mauricio Talks Knees and Regenerative Cell Therapy - Video

Australian researchers have made a breakthrough that could change the treatment of HIV and AIDS using gene therapy to block the progression of the disease.

T-Cell infected by HIV. (National Institute of Allergy and Infectious Diseases)

Published: Jan. 24, 2013 at 12:03 PM

Australian scientists may have hit upon a form a gene therapy that could lead to a cure for AIDS, causing the HIV virus to 'self-destruct.'

Queensland Institute of Medical Research researchers discovered a technique that changes how the HIV virus replicates in the body, creating a mutated form of the virus, the Australian Times reported.

Dr. David Harrich's team saw a breakthrough in 2007, when they discovered that the mutated HIV virus, known as Nullbasic, could block the process, called reverse transcription, that allows HIV to damage the immune system.

"With money running out, I had my PhD student try one more experiment in late 2007," Harrich told the Times. "The experiment was to test if Nullbasic could render HIV non-infectious. The student came back and said it worked, so I told him to do it again and again and again. It works every time.

Then backed by funding from the Australian Centre for HIV and Hepatitis research, Harrich's team was able to continue to test the theory that his Nullbasic gene therapy could block the exponential replication of the HIV virus.

"That study showed very clearly that it could protect human cells from HIV infection," Harrich said. "Subsequently we have protected primary human CD lymphocytes from blood from HIV infection using a gene therapy approach with outstanding results.

The increasing level of HIV, which becomes AIDS, cripples the immune system and leaves the infected individual susceptible to minor infections that their bodies would otherwise have no trouble fighting.

More:
Potential AIDS cure would make HIV virus 'self-destruct'

University of Texas researcher Edward Marcotte is neither a medical doctor nor a botanist. But using a computational algorithm, he found a connection between a disease causing deafness and a mustard plant that sometimes grows sideways. The same gene mutation causes both outcomes.

A computational algorithm is a kind of super-formula that sorts through massive sets of data to find problem-solving patterns. By focusing on proteins, which carry out the duties assigned to them by genes and are involved in almost all cell functions, Marcottes calculations have revealed numerous unlikely connections that are considered vital to understanding the inner workings of genetic diseases like cancer and heart disease.

Marcotte, 45, got his bachelors degree in molecular biology and a doctorate in biochemistry at UT, and describes his work in the chemistry and biochemistry department as basic biology. Marcotte likens himself to a kid turned loose on a playground to go exploring every day driven by all the potential discoveries just waiting to be found.

In fact, Marcotte could be considered something of an advertisement for the importance of pure as opposed to applied research. His objective, he says, is simply to understand what genes and proteins do. But its not so simple. Biologists are trying to figure out how genes work together and what each one does when its either active or inactive. These variations determine human biological characteristics, from eye color to the likelihood of developing a genetic disease.

Trying to find the tiny protein machines that make up cells and understanding those better should help with clinical research and applications, but thats not our goal, Marcotte said. Our goal is just to try to understand how cells work, to really figure out the parts to all these things.

For his work in that complicated arena, Marcotte was one of 10 scientists to win the National Institute of Healths 2012 Directors Pioneer Award. He and his research team at UT were awarded $3.85 million over the next five years to develop high-risk, high-reward technologies that would help scientists better interrogate the proteome, the set of proteins that serve as fingerprints for particular kinds of genes.

Ravi Basavappa, program director for the high-risk, high-reward research at the National Institute of Health said the technologies Marcotte proposed to develop have the clear potential to transform broad areas of biomedical science.

Such advanced work is now possible thanks to the worldwide effort to map the human genome, a project that took thousands of biologists, a billion dollars and most of the 1990s to accomplish. The process of reading a strand of DNA and revealing which genes are present and active can now be done by a machine that will sequence an entire genome, animal or vegetable, in about two days for $1,000.

Once you get the genome sequence, that tells you, in a way, the parts that an organism is capable of making and its particular version of those, Marcotte said.

The nearly 20,000 genes that make up the human genome serve as instructions on how to build proteins. Yet while biologists can now sequence a genome rapidly and with ease, they havent been able to look at a proteome, the entire set of proteins encoded by the genome, to the same degree.

Read more from the original source:
UT expert looks to new horizons in gene research

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--

Counsyl has partnered with ARUP Laboratories, a nonprofit enterprise of the University of Utah, to expand its pre-pregnancy and early pregnancy genetic test offering for prospective parents. ARUPs molecular genetic testing laboratory already provides a comprehensive set of testing options for a broad range of inherited disorders. The partnership with Counsyl complements ARUPs existing services for genomic medicine. Dr. Sherrie Perkins, Chief Medical Officer at ARUP, stated, We are pleased that the relationship with Counsyl now allows ARUP to offer testing for over 100 recessive genetic disorders to more than half of the nations university, teaching and childrens hospitals.

Included in the Counsyl Test are life-threatening conditions, such as spinal muscular atrophy, Smith-Lemli-Opitz, and Tay-Sachs disease. Several inherited metabolic disorders that can be treated with dietary modifications and supplements are also part of the test.

ARUP has historically used innovation and technology to support their clients need for specialty testing. For tests not performed at ARUP, high-quality test performance and exceptional clinical utility are the two primary criteria used to establish external partnerships. Counsyl uses high throughput technology to simultaneously screen for over 400 genetic variants from one tube of blood. Ramji Srinivasan, CEO of Counsyl, stated, Were energized about working with ARUP to make carrier screening a routine part of family planning across the country. Implicit in the partnership is a shared mission between Counsyl and ARUP to improve access to quality patient care while reducing healthcare costs.

About Counsyl

Counsyl makes genetic testing simple, accessible, and useful for important medical decisions. The Counsyl Test won the Wall Street Journals Innovation Award for Medicine, was named one of Scientific American's "Top 10 World Changing Ideas" and was featured in the New York Times. It is now offered at thousands of medical centers nationwide and covered by many insurers. For more information, visit http://www.counsyl.com.

Twitter: @counsyl

About ARUP Laboratories

Founded in 1984, ARUP Laboratories is a leading national reference laboratory and a nonprofit enterprise of the University of Utah and its Department of Pathology. ARUP offers more than 3,000 tests and test combinations, ranging from routine screening tests to esoteric molecular and genetic assays. ARUP serves clients across the United States, including many of the nations top university teaching hospitals and childrens hospitals, as well as multihospital groups, major commercial laboratories, group purchasing organizations, military and other government facilities, and major clinics. In addition, ARUP is a worldwide leader in innovative laboratory research and development, led by the efforts of the ARUP Institute for Clinical and Experimental Pathology.

Originally posted here:
ARUP to Offer Carrier Screening for Over 100 Genetic Disorders

27 January 2013| last updated at 11:36PM By R. Murali Rajaratenam, Kuala Lumpur

"Science has attained so much power that its practical limits begin to be apparent. Largely through science, billions of us live in one small world, densely packed and intercommunicating. But science cannot help us decide what to do with that world, or how to live. Science can make a nuclear reactor, but it cannot tell us not to build it. And our world starts to seem polluted in fundamental ways -- air, water and land -- because of ungovernable science."

It's been said that "all would be well if there were no 'buts'." Unfortunately, in genetics there are many "buts" and unwary traps for unsuspecting medical consumers.

So, if you have the choice of getting genetic testing, be sure you know of the pros and cons.

There's no doubt that genetic testing is a huge benefit under certain conditions. If a disease is caught early on, a patient has the best possible chance of survival. Understanding the advantages and disadvantages of genetic testing is important in deciding whether or not to undergo a test.

When this subject is discussed, most people think positively about genetic screening to diagnose for things like Down's syndrome. It would also be madness to bury one's head in the sand when there is a family history of colon cancer. By being aware that a faulty gene is present, regular colonoscopies can save lives by detecting polyps long before they become malignant.

If a genetic test demonstrates a predisposition towards an inherited disorder, the news can be depressing and a patient can be burdened with information over which he has no control.

However, knowledge of a predisposition may give the person enough time to take preventative measures, including taking medicine or adapting one's lifestyle to lower the risk of contracting a disease.

But what about the "buts"? A report in the Canadian Medical Association Journal points out the other side of the coin.

Dr James Evans, professor of genetics at the University of North Carolina in Chapel Hill, says: "We rarely in medicine do unalloyed good, some of the tools we employ are blunt so you had better have great information before you employ them."

Originally posted here:
GENETIC TESTING: Lifestyle plays a major role, too

Improve Lagging and Stubborn Muscle Groups
Like Share and Subscribe! It #39;s always appreciated! In this video I talk about how many of us have lagging body parts and people are quick to blame it on genetics. THe truth is that a lot of us have lagging body parts because we don #39;t give them the attention they need and deserve! The calves are the greatest example and I talk about that in this video! Supplements http://www.tigerfitness.com SAVE 5% off any supplement using code "fusaro" Clothing Sponsor Gym Shark Apparel: http://www.gymshark.co.uk Follow Me Here Facebook - http://www.facebook.com Instagram - mattyfusaro Twitter - @fusarofitness MyFitnessPal - http://www.myfitnesspal.com FusaroFitness Mailing Address: Matty Fusaro PO BOX 1746 Rocky Point, NY 11778 Message about monetization: This is an original video made by me and I own rights to all the content. I created this video with my own camera and used the editing software by Apple Final Cut Pro X. It contains no movies or tv visuals. I own all the pictures in it. There are no video games or performances.

By: Matty Fusaro

Read the rest here:
Improve Lagging and Stubborn Muscle Groups - Video

Kim Dotcom: File-sharing Kingpin Starts New Website
Welcome to downLOADED, the show where opinionated tech pundits gather around to discuss issues and news impacting technology and its users. This week we #39;re joined by Seth Rosenblatt, senior editor at CNET and PAtrick Norton, host of Revision3. Story Links: Kim Dotcom starts new file-sharing site The man behind the Megaupload.com is back at it again with a new site, mega.co.nz. Will it succeed where megaupload.com failed? http://www.bbc.co.uk Sony sells Manhattan headquarters skyscraper for $1.1bn Little more than a decade after purchasing the iconic Manhattan building Sony sells it for $1.1bn. Is this a much needed infusion of cash a sign of a desperate company or a shrewd conglomerate making a come back? http://www.bbc.co.uk Neanderthal man, DNA experiments and the shadow of Dr Frankenstein George Church is a genetics professor at Harvard Medical School who believes he can give birth to a Nederthal using reconstructed DNA from fossils and a modern DNA sequencing computers. All he needs is the consent and womb of a willing woman. Is technology making a modern day Frankenstein possible? - http://www.dailymail.co.uk Brin wears his Google glasses on NYC subway! Sergey Brin caught wearing Google glasses on NY subway. Why? news.cnet.com

By: TheTechFeed

Read this article:
Kim Dotcom: File-sharing Kingpin Starts New Website - Video

The Art of Love (at Herzog Hospital) for you to Share
If this you know someone who might need help or advice in any of Herzog Hospitals areas of their expertise then....Share this video with them and have them visit http://www.afherzoghospital.org Herzog has an outstanding international reputation for its Research Department #39;s groundbreaking work in behavioral genetics, schizophrenia, Alzheimer #39;s and Parkinson #39;s Diseases, addiction, ADD/ADHD (Attention Deficit and Hyperactivity Disorder). More info about the Hospital.... Herzog Hospital is Israel #39;s foremost center for geriatric, respiratory and mental health care. With 330 beds, it is the third largest hospital in Jerusalem. A new Children #39;s Chronic Respiratory Care Department treats children ranging in age from 4 months to 18 years. Herzog #39;s Israel Center for the Treatment of Psychotrauma treats children and adult victims of terror attacks, war and domestic violence, and provides training in Israel and internationally. The Hospital #39;s Department of Research is internationally recognized for its work in behavioral genetics. Due to the dramatic growth of Herzog Hospital, a new wing is being constructed to add 240 much needed beds

By: Jason Sigman

Link:
The Art of Love (at Herzog Hospital) for you to Share - Video